Last reviewed · How we verify
MVA.HIVconsv vaccine
At a glance
| Generic name | MVA.HIVconsv vaccine |
|---|---|
| Sponsor | IrsiCaixa |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals (PHASE1)
- Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals (PHASE1)
- Research In Viral Eradication of HIV Reservoirs (PHASE2)
- Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination (PHASE1, PHASE2)
- A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination (PHASE1)
- Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART (PHASE1)
- Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults (PHASE1, PHASE2)
- Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MVA.HIVconsv vaccine CI brief — competitive landscape report
- MVA.HIVconsv vaccine updates RSS · CI watch RSS
- IrsiCaixa portfolio CI